Next Article in Journal
The Role of Red Cell Distribution Width in the Differential Diagnosis of Iron Deficiency Anemia and Non-Transfusion-Dependent Thalassemia Patients
Previous Article in Journal
Acquired Hemophilia A Developing Cerebral Infarction 36 Days after the Frequent Administration of Bypass Hemostatic Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 10
Issue 3
10.4081/hr.2018.7474
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Clinical Significance of Dasatinib-Induced Pleural Effusion in Patients with De Novo Chronic Myeloid Leukemia

by
Aya Nakaya
*,
Shinya Fujita
,
Atsushi Satake
,
Takahisa Nakanishi
,
Yoshiko Azuma
,
Yukie Tsubokura
,
Masaaki Hotta
,
Hideaki Yoshimura
,
Kazuyoshi Ishii
,
Tomoki Ito
and
Shosaku Nomura
First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata 573-1010, Osaka, Japan
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2018, 10(3), 7474; https://doi.org/10.4081/hr.2018.7474
Submission received: 1 November 2017 / Revised: 2 June 2018 / Accepted: 27 June 2018 / Published: 5 September 2018

Abstract

Dasatinib is currently approved for clinical use as a first-line treatment agent for newly diagnosed chronic myeloid leukemia (CML). However, only a few clinical trials have been performed to evaluate dasatinibinduced PE following first-line therapy. We investigated the incidence and clinical features of dasatinib-induced PE following first-line therapy in Japanese CML patients of real world clinical practice settings. Among 22 patients, the median age of PE-positive patients was higher than that of PE-negative patients. Major molecular response was achieved in 75% of PE-positive patients and 50% of PE-negative patients. Most patients developed PE more than 1 year after treatment. Appearance of PE is associated with better clinical response during dasatinib treatment, however it is developed at any time. Elderly and high-risk patients tend to develop PE. The clinical features of dasatinib-induced PE following first-line therapy might be late onset and might not immediately follow the increasing of large granular lymphocyte.
Keywords: chronic myeloid leukemia; dasatinib; large granular lymphocyte; pleural effusion; late-onset; adverse event chronic myeloid leukemia; dasatinib; large granular lymphocyte; pleural effusion; late-onset; adverse event

Share and Cite

MDPI and ACS Style

Nakaya, A.; Fujita, S.; Satake, A.; Nakanishi, T.; Azuma, Y.; Tsubokura, Y.; Hotta, M.; Yoshimura, H.; Ishii, K.; Ito, T.; et al. Clinical Significance of Dasatinib-Induced Pleural Effusion in Patients with De Novo Chronic Myeloid Leukemia. Hematol. Rep. 2018, 10, 7474. https://doi.org/10.4081/hr.2018.7474

AMA Style

Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Hotta M, Yoshimura H, Ishii K, Ito T, et al. Clinical Significance of Dasatinib-Induced Pleural Effusion in Patients with De Novo Chronic Myeloid Leukemia. Hematology Reports. 2018; 10(3):7474. https://doi.org/10.4081/hr.2018.7474

Chicago/Turabian Style

Nakaya, Aya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, and et al. 2018. "Clinical Significance of Dasatinib-Induced Pleural Effusion in Patients with De Novo Chronic Myeloid Leukemia" Hematology Reports 10, no. 3: 7474. https://doi.org/10.4081/hr.2018.7474

Article Metrics

Back to TopTop